The report published by medical journal The Lancet said every participant developed antibodies to fight the virus and had no serious side effects .
"The two 42-day trials - including 38 healthy adults each - did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response," The Lancet said.
Russian President Vladimir Putin's announcement on August 13 that Russia had become the first country to grant regulatory approval to a COVID-19 vaccine raised scepticism.
The participants - aged between 18 and 60 - were monitored for 42 days and all of them developed antibodies within three weeks. Among the most common side effects were headaches and joint pain.
The
trials were open label and not randomised, meaning there was no placebo
and the volunteers were aware they were receiving the vaccine.
"Large,
long-term trials including a placebo comparison, and further monitoring
are needed to establish the long-term safety and effectiveness of the
vaccine for preventing Covid-19 infection," the report said.
No comments:
Post a Comment